IL6 and pancreatitis: Orlistat was shown to decrease IL-6 and TNFα in diabetic patients [120], and to reduce systemic inflammation and pancreatitis-induced death in obese (ob/ob) mice as measured by a lower mortality incidence and decreased serum levels of TNFα, MCP-1 and IL-6 in an acute pancreatitis mouse model [121].